title: A novel prognostic score model incorporating CDGSH iron sulfur domain2 (CISD2) predicts risk of disease progression in laryngeal squamous cell carcinoma.
abstract: BACKGROUND
  The role of CDGSH iron sulfur domain 2 (CISD2) in laryngeal squamous cell carcinoma (LSCC) remains unclear.
  
  
  RESULTS
  CISD2 were up-regulated in LSCC tissues compared with adjacent noncancerous tissues both at mRNA and protein levels. CISD2 was significantly correlated with T stage, lymph node metastasis, clinical stage and disease progression. A prognostic model (C-N model) for PFS was subsequently constructed based on independent prognostic factors including CISD2 and N classification. This model significantly divided LSCC patients into three risk subgroups and was more accurate than the prediction efficacy of TNM classification in the training cohort (C-index, 0.710 vs 0.602, P = 0.027) and validation cohort (C-index, 0.719 vs 0.578, P = 0.014).
  
  
  METHODS
  Real-time PCR and Western blotting were employed to examine the expression of CISD2 in eight fresh paired LSCC samples. Immunohistochemistry was performed to assess CISD2 expression in 490 paraffin-embedded archived LSCC samples. A prognostic model for progression-free survival (PFS) was built using independent factors. The concordance index (C-Index) was used to evaluate the prognostic ability of the model.
  
  
  CONCLUSIONS
  CISD2 was up-regulated in LSCC. The novel C-N model, which includes CISD2 levels and N classification, is more accurate than conventional TNM classification for predicting PFS in LSCC.
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.|State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Yang
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.|State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Shaodong
authors.initials: S
authors.lastname: Hong
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.|State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.|State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Zhenyu
authors.initials: Z
authors.lastname: He
authors.affiliation: The First Hospital of Foshan, Foshan 528000, China.
authors.forename: Shaobo
authors.initials: S
authors.lastname: Liang
authors.affiliation: The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510060, China.
authors.forename: Haiyang
authors.initials: H
authors.lastname: Chen
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.|State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Shasha
authors.initials: S
authors.lastname: He
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.|State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Shu
authors.initials: S
authors.lastname: Wu
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.|State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Libing
authors.initials: L
authors.lastname: Song
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.|State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology*; D006801:Humans; D053208:Kaplan-Meier Estimate; D007822:Laryngeal Neoplasms / Q000401:mortality / Q000473:pathology*; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis*; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D000077195:Squamous Cell Carcinoma of Head and Neck; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C523851:CISD2 protein, human; D008565:Membrane Proteins
keywords: CDGSH iron sulfur domain2 (CISD2); biomarker; laryngeal squamous cell carcinoma (LSCC); progression free survival (PFS)